These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 32220422)

  • 1. The host's angiotensin-converting enzyme polymorphism may explain epidemiological findings in COVID-19 infections.
    Delanghe JR; Speeckaert MM; De Buyzere ML
    Clin Chim Acta; 2020 Jun; 505():192-193. PubMed ID: 32220422
    [No Abstract]   [Full Text] [Related]  

  • 2. [Genetic and epigenetic variability, and the Covid-19 pandemic].
    Rivera-Silva G
    Salud Publica Mex; 2020; 62(5):462-463. PubMed ID: 32668509
    [No Abstract]   [Full Text] [Related]  

  • 3. Could angiotensin-converting enzyme 1
    Dević Pavlić S; Nadalin S; Starčević Čizmarević N; Buretić-Tomljanović A; Radojčić Badovinac A; Ristić S
    J Renin Angiotensin Aldosterone Syst; 2020; 21(3):1470320320957157. PubMed ID: 32928023
    [No Abstract]   [Full Text] [Related]  

  • 4. Genetic predisposition models to COVID-19 infection.
    Darbeheshti F; Rezaei N
    Med Hypotheses; 2020 Sep; 142():109818. PubMed ID: 32416414
    [No Abstract]   [Full Text] [Related]  

  • 5. Genetic Associations With Plasma Angiotensin Converting Enzyme 2 Concentration: Potential Relevance to COVID-19 Risk.
    Nelson CP; Sama IE; Codd V; Webb TR; Ye S; Lang CC; Voors AA; Ng LL; Samani NJ
    Circulation; 2020 Sep; 142(11):1117-1119. PubMed ID: 32795093
    [No Abstract]   [Full Text] [Related]  

  • 6. [Are there genetic variants that can modify the course of the COVID-19 pandemic?].
    Azurmendi PJ
    Medicina (B Aires); 2020; 80 Suppl 3():79-81. PubMed ID: 32658852
    [No Abstract]   [Full Text] [Related]  

  • 7. COVID-19 infections are also affected by human ACE1 D/I polymorphism.
    Delanghe JR; Speeckaert MM; De Buyzere ML
    Clin Chem Lab Med; 2020 Jun; 58(7):1125-1126. PubMed ID: 32286246
    [No Abstract]   [Full Text] [Related]  

  • 8. Sex-mediated effects of ACE2 and TMPRSS2 on the incidence and severity of COVID-19; The need for genetic implementation.
    Alshahawey M; Raslan M; Sabri N
    Curr Res Transl Med; 2020 Nov; 68(4):149-150. PubMed ID: 32917573
    [No Abstract]   [Full Text] [Related]  

  • 9. A suspicious role of interferon in the pathogenesis of SARS-CoV-2 by enhancing expression of ACE2.
    Su S; Jiang S
    Signal Transduct Target Ther; 2020 May; 5(1):71. PubMed ID: 32435059
    [No Abstract]   [Full Text] [Related]  

  • 10. ACE2 Expression and Risk Factors for COVID-19 Severity in Patients with Advanced Age.
    Tavares CAM; Avelino-Silva TJ; Benard G; Cardozo FAM; Fernandes JR; Girardi ACC; Jacob Filho W
    Arq Bras Cardiol; 2020 Oct; 115(4):701-707. PubMed ID: 33111872
    [No Abstract]   [Full Text] [Related]  

  • 11. Coronavirus in Hematologic Malignancies: Targeting Molecules Beyond the Angiotensin-Converting Enzyme 2 (ACE2) Wall in COVID-19.
    Tsiambas E; Papanikolaou V; Chrysovergis A; Mastronikolis N; Ragos V; Kavantzas N; Lazaris AC; Kyrodimos E
    Pathol Oncol Res; 2020 Oct; 26(4):2823-2825. PubMed ID: 32333199
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin Converting Enzyme-2 (ACE2) Receptors, asthma and severe COVID-19 infection risk.
    Öztürk AB; Çağlayan B
    Eur Ann Allergy Clin Immunol; 2020 Nov; 52(6):282-285. PubMed ID: 32914945
    [No Abstract]   [Full Text] [Related]  

  • 13. Covid-19 infection and the host genetic predisposition: does it exist?
    Vašků A
    Physiol Res; 2020 Jul; 69(3):511-514. PubMed ID: 32682363
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Host Polymorphisms May Impact SARS-CoV-2 Infectivity.
    Brest P; Refae S; Mograbi B; Hofman P; Milano G
    Trends Genet; 2020 Nov; 36(11):813-815. PubMed ID: 32828550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SARS-CoV-2 Infections: An ACE in the Hole and Systems Biology Studies-a Research Agenda.
    Poland GA; Bass J; Goldstein MR
    Mayo Clin Proc; 2020 Sep; 95(9):1838-1841. PubMed ID: 32861326
    [No Abstract]   [Full Text] [Related]  

  • 16. Alternative splicing of ACE2 possibly generates variants that may limit the entry of SARS-CoV-2: a potential therapeutic approach using SSOs.
    Rehman SU; Tabish M
    Clin Sci (Lond); 2020 May; 134(10):1143-1150. PubMed ID: 32442315
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Cell RNA Expression Profiling of ACE2, the Receptor of SARS-CoV-2.
    Zhao Y; Zhao Z; Wang Y; Zhou Y; Ma Y; Zuo W
    Am J Respir Crit Care Med; 2020 Sep; 202(5):756-759. PubMed ID: 32663409
    [No Abstract]   [Full Text] [Related]  

  • 18. ACE Ins/Del genetic polymorphism and epidemiological findings in COVID-19.
    Delanghe JR; Speeckaert MM; De Buyzere ML
    Clin Chem Lab Med; 2020 Jun; 58(7):1129-1130. PubMed ID: 32386189
    [No Abstract]   [Full Text] [Related]  

  • 19. Robust and persistent SARS-CoV-2 infection in the human intestinal brush border expressing cells.
    Lee S; Yoon GY; Myoung J; Kim SJ; Ahn DG
    Emerg Microbes Infect; 2020 Dec; 9(1):2169-2179. PubMed ID: 32969768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes.
    Debnath M; Banerjee M; Berk M
    FASEB J; 2020 Jul; 34(7):8787-8795. PubMed ID: 32525600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.